News Release
Poolbeg Pharma and CytoReason identify "very exciting influenza targets"
Poolbeg Pharma PLC
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after announcing what they call a "significant breakthrough" in their world-first influenza Artificial Intelligence ('AI') Programme. Skillington says that the collaboration has yielded some "very exciting influenza targets" and that Poolbeg will now be "actively exploring the most effective way to bring them forward into development." He also highlights Poolbeg's RSV-focused AI collaboration with CytoReason that concluded in 2022, saying that Poolbeg "is now working on validating those targets... and will have data before the end of the year." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
June 29, 2023 03:54 AM Eastern Daylight Time
Video
News Release
TransCode Therapeutics making preclinical progress with lead metastatic cancer candidate
TransCode Therapeutics Inc
TransCode Therapeutics CEO Michael Dudley joined Proactive's Natalie Stoberman to share the latest progress from its lead RNA oncology candidate TTX-MC138. TransCode is an RNA oncology company created on the belief that cancer can be more effectively treated using RNA therapeutics. The company has created a platform of drug candidates designed to target a variety of tumour types with the objective of significantly improving patient outcomes. TransCode's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which is believed to cause approximately 90% of all cancer deaths totalling over nine million per year worldwide. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com
June 28, 2023 03:49 PM Eastern Daylight Time
Video
News Release
Tonix Pharmaceuticals fibromyalgia study published in American College of Rheumatology
Tonix Pharmaceuticals
Tonix Pharmaceuticals CEO Seth Lederman joined Proactive's Natalie Stoberman to discuss the recent publication of the company's Phase 3 study on TNX-102 SL for fibromyalgia management in the American College of Rheumatology. Lederman said the article outlined how the study's results showed improvements in widespread pain and fatigue, which are significant symptoms of fibromyalgia. He explains that TNX-102 SL, a sublingual tablet taken at bedtime, targets sleep quality to enhance overall fibromyalgia symptoms. With the upcoming confirmatory Phase 3 trial results, Lederman said Tonix aims to file a new drug application for TNX-102 SL. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com
June 28, 2023 03:21 PM Eastern Daylight Time
Video
News Release
Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial
Atossa Therapeutics Inc
Atossa Therapeutics CEO Steven Quay joined Proactive's Natalie Stoberman to discuss the latest progress in its Phase 2 I-SPY 2 clinical trial where six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, achieving a 30 percent enrollment rate within two months of the trial commencing. The I-SPY 2 TRIAL is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium. The (Z)-endoxifen treatment arm, which is expected to enroll approximately 20 patients, is part of the I-SPY 2 Endocrine Optimization Pilot Protocol (EOP). Patients will receive 10 mg of (Z)-endoxifen daily for up to 24 weeks prior to surgery. Currently, there are 41 I-SPY 2 sites, all of which have the EOP program open. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com
June 28, 2023 01:03 PM Eastern Daylight Time
Video
News Release
BioVie building healthier future for families and caregivers dealing with neurodegenerative diseases
BioVie Inc
BioVie Chief Social Impact Officer Sarah Hoit joined Proactive's Natalie Stoberman to bring more awareness to Alzheimer's and Brain Awareness month. Hoit shared how the company's initiatives are trying to positively impact the families and caregivers, as well as finding alternatives to ease the stress of neurodegenerative diseases on the healthcare system and the economy. Hoit said BioVie continues to create more impact investment opportunities with new trials and initiatives on the horizon. But most importantly, Hoit said the growth of BioVie's Social Impact Partners Foundation has been growing to create a global consortium of leaders and organizations to impact brain health and create a healthier future through fundraising, resource mobilization and industry collaboration. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com
June 28, 2023 12:59 PM Eastern Daylight Time
Video
News Release
Living with Myasthenia Gravis: The Rare Autoantibody Disease That Causes Muscle Weakness and Severe Fatigue
YourUpdateTV
A video accompanying this announcement is available at: https://youtu.be/-FuYn9PdBdI What would you do if you began to have symptoms of drooping eyelids and difficulty speaking? A rare and unfamiliar condition that turned to a daily struggle to chew, swallow, smile, see, or even lift your arms, legs, and neck. That is what happened to Meridith O’Connor at the age of 13 and after two long years of doctor visits, she was finally diagnosed with myasthenia gravis, also known as MG. Myasthenia gravis is a chronic autoantibody condition of the nervous system that affects muscle strength and makes everyday activities like standing, blinking, swallowing, and moving your arms challenging. MG is a highly debilitating rare disease for which there currently is no cure. As many as 60,000 Americans, and 700,000 people worldwide are living with the condition. June is Myasthenia Gravis Awareness Month, which provides an opportunity for people around the world to recognize the impact of MG. On June 26th a media tour was conducted with Meridith O’Connor, Assistant Vice President of Patient Engagement, Advocacy, and Policy for the Myasthenia Gravis Foundation of America (MGFA), and Dr. Nicholas Silvestri, an associate professor of neurology at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, to learn the latest on the disease and how it affects those living with it. Approximately 85% of people living with MG experience the more extensive form of the disease, generalized myasthenia gravis (gMG). MG affects both men and women and occurs across all ages and racial and ethnic groups. However, it most commonly impacts young adult women and older men. Diagnosis is often a long, frustrating, and painful journey for patients. This is because muscle weakness is a common symptom of many disorders, and symptoms can fluctuate. Patients often face months or years of untreated symptoms before they receive an accurate diagnosis, which is why they are often diagnosed at an older age. Despite availability of treatment options, significant unmet need persists, as up to 20% of patients do not respond to existing treatments and are left with no effective therapeutic options. Research is needed to develop new treatments for those who may not respond well and/or tolerate current therapies. FOR MORE INFORMATION VISIT: IMAGINEMYMG.COM THIS MEDIA TOUR IS BROUGHT TO YOU BY THE JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com
June 28, 2023 10:02 AM Eastern Daylight Time
Video
News Release
Chill Brands Group CEO takes aim at "moral panic" around vaping
Chill Brands Group PLC
Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) CEO Callum Sommerton speaks to Thomas Warner from Proactive about recent additions to the product range on offer at Chill.com, the performance of the business during the first half of calendar year 2023 and his hopes for the coming months. He reiterates his commitment to launching nicotine-free vapes in the UK market, saying that "the second half of this year is all about that activation", and says Chill Brands is "proving wrong the doubters in relation to what I suggest is a moral panic around vaping that's happening in the UK at the moment." Chill is already marketing nicotine-free vapes in the US, and Sommerton says that he's already "getting great data from our US pilot stores." Contact Details UK Editorial +44 20 7989 0813 uk@proactiveinvestors.com
June 28, 2023 08:08 AM Eastern Daylight Time
Video
News Release
Creo Medical Group gets "great results" from first upper GI use of Speedboat Inject in Europe
Creo Medical Group PLC
Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford speaks to Thomas Warner from Proactive after the medical device company announced that the first upper gastrointestinal (GI) procedure in Europe has been carried out using the company's Speedboat Inject product. Gulliford says that the procedure to remove a cancer from a patient's stomach was successfully completed by Adolfo Parra-Blanco at Nottingham University Hospitals, with the "great results... we've come to expect." Gulliford also explains why Creo is now looking for a new Chairman to help develop the company internationally. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
June 28, 2023 08:05 AM Eastern Daylight Time
Video
News Release
hVIVO to develop first commercial hMPV human challenge model
hVIVO PLC
hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has partnered with a North American biopharmaceutical company to create the industry's first commercial hMPV human challenge model. Khan says he's "very happy with the signing of this contract" before going to explain the significance of the news for hVIVO investors as well as for patients. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com
June 28, 2023 07:42 AM Eastern Daylight Time
Video
